Sponsored by Eurofins DiscoverX
During the development of antibody therapeutics, regulators now require assays to evaluate Fc effector function demonstrating immune cell-mediated killing via ADCC and ADCP rather than a surrogate endpoint for antibody engagement of antigen on target cells. Eurofins DiscoverX’s KILR® cytotoxicity assay platform specifically measures antibody-mediated killing of antigen-expressing target cells in co-culture with effector cells. This platform is now available as ready-to-use bioassays for several tumor models, including Raji and Daudi, for use in screening and lot-release applications. These bioassays are qualified with Rituximab and demonstrate high repeatability and inter-analyst performance.
Abzena, an integrated early discovery to mid-phase biotherapeutics development services provider, independently evaluated KILR Raji Bioassay cells in both ADCC and ADCP assays to offer clients a robust platform for ranking and characterization studies.
In this webinar, we demonstrate that these bioassay cells show excellent reproducibility in ADCC assays with both KILR CD16 Effector Cells and PBMCs. We will show that the bioassay cells provide a quantitative readout for ADCP, with a large assay window and high signal-to-background ratios.